The European Alliance for Personalised Medicine (EAPM) participated in the Focus on TOP – Translational Oncology and Precision Medicine in Breast Cancer symposium, held on 23–24 March 2026 in Udine.

The symposium brought together a diverse, interdisciplinary community of clinicians, translational researchers, digital experts, patient advocates, and policymakers to explore the evolving landscape of breast cancer management. As innovation continues to accelerate, driven by novel therapies and emerging technologies, the discussions highlighted the growing need to align scientific progress with sustainability, governance frameworks, and real-world implementation.

EAPM was represented by Denis Horgan, who contributed to discussions focused on bridging the gap between research and clinical practice, and ensuring that advances in precision oncology translate into tangible patient outcomes across European health systems.

The two-day programme provided a structured platform for both strategic reflection and practical exchange. Key areas of focus included regulatory and sustainability challenges, as well as the latest developments in clinical and translational oncology. The importance of cross-sector collaboration emerged as a central theme, reinforcing the need for coordinated efforts across stakeholders to deliver impactful and scalable solutions.

A highlight of the symposium was the PORTRAIT/PMAC Workshop, a translational “hackathon” format enabling participants to co-develop solutions to real-world research challenges. This interactive approach underscored the shift towards more applied, solution-oriented models of collaboration in oncology.

Scientific coordination of the event included leading experts such as Lorenzo Gerratana and Carolina Reduzzi, reflecting the high level of expertise driving the programme.

EAPM’s participation reaffirmed its ongoing commitment to fostering multi-stakeholder dialogue and supporting policy frameworks that enable the effective integration of innovation into healthcare systems. Insights from the symposium will feed into EAPM’s continued work on advancing personalised medicine and strengthening policy pathways for precision oncology across Europe.